| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
tumor protein p53 | 0.236 | 0.962 | 0.53 |
|
phenotype | 0.600 | None | 0.936 | 578 | 13 | 1991 | 2020 | ||||||||
|
epidermal growth factor receptor | 0.295 | 0.885 | 0.37 |
|
phenotype | 0.400 | None | 0.973 | 520 | 10 | 1988 | 2020 | ||||||||
|
erb-b2 receptor tyrosine kinase 2 | 0.328 | 0.923 | 6.0E-03 |
|
phenotype | 0.600 | None | 0.970 | 560 | 7 | 1989 | 2020 | ||||||||
|
KRAS proto-oncogene, GTPase | 0.320 | 0.923 | 7.9E-04 |
|
phenotype | 0.400 | None | 0.952 | 207 | 7 | 1991 | 2020 | ||||||||
|
B-Raf proto-oncogene, serine/threonine kinase | 0.319 | 0.846 | 1.00 |
|
phenotype | 0.100 | None | 0.932 | 280 | 6 | 2003 | 2020 | ||||||||
|
ret proto-oncogene | 0.392 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 0.940 | 50 | 6 | 1992 | 2020 | ||||||||
|
androgen receptor | 0.351 | 0.846 | 0.99 |
|
phenotype | 0.100 | None | 0.986 | 145 | 5 | 1997 | 2020 | ||||||||
|
vascular endothelial growth factor A | 0.266 | 0.923 | 2.4E-05 |
|
phenotype | 0.400 | None | 0.976 | 503 | 4 | 1994 | 2020 | ||||||||
|
matrix metallopeptidase 9 | 0.305 | 0.923 | 1.9E-17 |
|
phenotype | 0.600 | None | 0.991 | 450 | 4 | 1996 | 2020 | ||||||||
|
C-X-C motif chemokine receptor 4 | 0.362 | 0.923 | 1.8E-02 |
|
phenotype | 0.400 | None | 0.989 | 374 | 4 | 2000 | 2020 | ||||||||
|
NRAS proto-oncogene, GTPase | 0.390 | 0.808 | 0.49 |
|
phenotype | 0.100 | None | 0.955 | 44 | 4 | 1995 | 2020 | ||||||||
|
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.292 | 0.923 | 1.00 |
|
phenotype | 0.400 | None | 0.976 | 291 | 3 | 2003 | 2020 | ||||||||
|
estrogen receptor 1 | 0.324 | 0.962 | 1.00 |
|
phenotype | 0.400 | None | 0.962 | 234 | 3 | 1992 | 2020 | ||||||||
|
MET proto-oncogene, receptor tyrosine kinase | 0.380 | 0.846 | 0.97 |
|
phenotype | 0.400 | None | 0.972 | 142 | 3 | 1995 | 2020 | ||||||||
|
high mobility group box 1 | 0.368 | 0.923 | 0.82 |
|
phenotype | 0.100 | None | 0.985 | 67 | 3 | 2003 | 2020 | ||||||||
|
advanced glycosylation end-product specific receptor | 0.420 | 0.885 | 6.4E-16 |
|
phenotype | 0.100 | None | 1.000 | 30 | 3 | 2002 | 2019 | ||||||||
|
mechanistic target of rapamycin kinase | 0.343 | 0.885 | 1.00 |
|
phenotype | 0.300 | None | 1.000 | 30 | 3 | 2010 | 2019 | ||||||||
|
CD47 molecule | 0.468 | 0.769 | 0.92 |
|
phenotype | 0.100 | None | 0.947 | 19 | 3 | 1997 | 2020 | ||||||||
|
nuclear factor kappa B subunit 1 | 0.396 | 0.923 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 17 | 3 | 2003 | 2018 | ||||||||
|
ERCC excision repair 1, endonuclease non-catalytic subunit | 0.445 | 0.846 | 1.6E-07 |
|
phenotype | 0.400 | None | 0.917 | 12 | 3 | 2008 | 2019 | ||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
phenotype | 0.100 | None | 1.000 | 11 | 3 | 2013 | 2019 | |||||||||
|
autophagy related 5 | 0.462 | 0.885 | 0.98 |
|
phenotype | 0.040 | None | 1.000 | 4 | 3 | 2014 | 2019 | ||||||||
|
H3.3 histone A | 0.559 | 0.692 | 0.12 |
|
phenotype | 0.020 | None | 1.000 | 2 | 3 | 2016 | 2019 | ||||||||
|
exonuclease 1 | 0.578 | 0.692 | 8.1E-13 |
|
phenotype | 0.020 | None | 1.000 | 2 | 3 | 2005 | 2019 | ||||||||
|
CD44 molecule (Indian blood group) | 0.363 | 0.962 | 2.4E-07 |
|
phenotype | 0.400 | None | 0.979 | 327 | 2 | 1990 | 2020 |